与AFG2A相关的脑病变:性饮食在和线粒体动力学调节中的有效性
Laia Nou-Fontanet1, Uliana Musokhranova2, Alia Ramírez Camacho1
1Neurology and Neurophysiology Department, Neurometabolic, MetabERN and Early Onset Epilepsy and Epilepsy Units, Hospital Sant Joan de Déu, CIBERER-ISCIII and ERN-Epicare Coordinator Centre, Esplugues de Llobregat, Spain; Complex Epilepsies Research Group, Institut de Recerca de Sant Joan de Déu, Esplugues de Llobregat, Spain.
概括
性饮食 (KD) 显示出治疗AFG2A相关脑病变 (AFG2A-RE) 与耐药性 (DRE) 的前景. 儿童早期的干预可以改善这些患者的控制和线粒体功能.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 与AFG2A相关的脑病变 (AFG2A-RE) 是一种神经发育障碍,经常伴随着耐药性 (DRE).
- 线粒体功能障碍与神经发育障碍有关,但其在AFG2A-RE中的特定作用需要进一步阐明.
- 目前对DRE的AFG2A-RE的治疗选择有限,需要探索新的治疗策略.
研究的目的:
- 评估基因饮食 (KD) 在治疗 AFG2A-RE.RE 患者的 DRE 中的临床疗效.
- 研究KD对患者衍生纤维细胞的线粒体形态,动态和新陈代谢的影响.
- 探索KD作为AFG2A-RE治疗干预的潜力.
主要方法:
- 一项描述性和实验性研究,涉及5名患有AFG2A-RE和DRE的患者.
- 在KD治疗后,评估了临床结果,包括发作减少和家长的总体印象.
- 来自患者的纤维细胞在KD模仿媒介 (KD-MM) 中培养,以评估线粒体功能和形态.
主要成果:
- 五分之四的患者经历了从0%到100%的发作减少与KD治疗.
- 在一些患者中观察到社会互动,注意力和运动功能的改善.
- 实验室研究表明,KD-MM可以逆转线粒体异常,包括改变形态,减少ATP的产生,并在AFG2A缺陷纤维细胞中正常化ROS水平.
结论:
- 性饮食 (KD) 证明了AFG2A相关脑病变 (AFG2A-RE) 与耐药性 (DRE) 的潜在治疗益处.
- 在童年早期早期启动KD可能会增强控制.
- 通过多中心前性研究进行进一步验证是有必要的,以证实这些初步发现.
相关概念视频
01:40Overview of Metabolism
32.0K
Living cells constantly carry out various chemical reactions which are necessary for their proper functioning. These reactions are interlinked to one another via multiple pathways. The collection of these chemical reactions is known as metabolism.
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
32.0K
01:14Antiepileptic Drugs: Glutamate Antagonists
517
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
517
01:20Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
653
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
653
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
451
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
451
01:24Epilepsy and Seizures: Overview
281
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
281